Loading...
XNASPRPH
Market cap18mUSD
Dec 31, Last price  
0.76USD
1D
5.23%
1Q
-68.45%
Name

Prophase Labs Inc

Chart & Performance

D1W1MN
XNAS:PRPH chart
P/E
—
P/S
0.41
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.59%
Rev. gr., 5y
27.59%
Revenues
44m
-63.81%
43,947,99553,658,04342,124,96939,475,38120,506,61219,816,00014,502,00017,453,00022,406,00025,032,00022,070,00020,604,00021,014,0009,867,00013,126,0009,876,00014,514,00079,042,000122,647,00044,384,000
Net income
-17m
L
452,8623,216,684-1,748,345-2,458,337-5,534,286-3,842,000-3,501,000-2,710,000-1,091,000405,000-7,834,000-3,600,000-2,868,00041,831,000-1,740,000-3,013,000-2,420,0006,273,00018,463,000-16,782,000
CFO
-11m
L
4,660,0274,265,489956,943-1,311,598-3,057,592445,000-3,549,000-2,108,000-5,729,0001,137,000-3,216,000-3,497,000-472,000-2,838,000-2,119,000-841,000-2,592,000-13,619,00028,551,000-11,348,000
Dividend
May 24, 20220.3 USD/sh
Earnings
Mar 13, 2025

Profile

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
URL
https://www.prophaselabs.com/
IPO date
Jan 16, 1984
Employees
129
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
44,384
-63.81%
122,647
55.17%
Cost of revenue
64,065
99,052
Unusual Expense (Income)
NOPBT
(19,681)
23,595
NOPBT Margin
19.24%
Operating Taxes
(6,018)
4,445
Tax Rate
18.84%
NOPAT
(13,663)
19,150
Net income
(16,782)
-190.90%
18,463
194.32%
Dividends
(9,353)
Dividend yield
5.21%
Proceeds from repurchase of equity
(5,967)
4,892
BB yield
7.67%
-2.72%
Debt
Debt current
2,793
301
Long-term debt
29,709
11,219
Deferred revenue
1,100
1,059
Other long-term liabilities
2,000
Net debt
27,766
(5,917)
Cash flow
Cash from operating activities
(11,348)
28,551
CAPEX
(3,155)
(3,919)
Cash from investing activities
(1,369)
(2,077)
Cash from financing activities
5,757
(26,023)
FCF
(20,227)
19,473
Balance
Cash
4,736
17,437
Long term investments
Excess cash
2,517
11,305
Stockholders' equity
(5,311)
12,526
Invested Capital
79,174
56,155
ROIC
32.80%
ROCE
34.86%
EV
Common stock shares outstanding
17,207
18,651
Price
4.52
-53.06%
9.63
46.58%
Market cap
77,776
-56.70%
179,609
48.63%
EV
105,542
173,692
EBITDA
(12,983)
28,656
EV/EBITDA
6.06
Interest
1,275
764
Interest/NOPBT
3.24%